11:32 AM EDT, 06/18/2024 (MT Newswires) -- Arch Biopartners ( ACHFF ) said Tuesday the University of Calgary's Conjoint Health Research Ethics Board approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury.

The clinical team at the University of Calgary Cumming School of Medicine is now able to work with Arch to complete preparation and training to enable the start of patient recruitment in Calgary. This work will be completed while waiting for the expected final approval from Alberta Health Services.

The trial continues to have patient recruitment at five clinical sites in Turkey. Since patients dosing began in March, there have been enhancements to the design of the study protocol to help improve the execution of the trial. These changes have since been approved by Health Canada and are pending approval by the Turkish Ministry of Health, the company said.

Arch shares were last seen up $0.03 to $1.69 on the TSX Venture Exchange.

Price: 1.69, Change: +0.03, Percent Change: +1.81